4Ahn J K, Moon H J. Changes in aqueous vascular endo- thelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration [ J ]. Am J Ophthalmol, 2009,148 ( 5 ) :718-724.
5Matsuyama K, Ogata N, Matsuoka M, et al. Plasma lev- els of vascular endothelial growth factor and pigment epi- thelium-derived factor before and after intravitreal injec- tion of bevacizumab[ J]. Br J Ophthalmol, 2010,94 ( 9 ) : 1215-1218.
6Massin P, Bandello F, Garweg J G, et al. Safety and ef- ficacy of ranibizumab in diabetic macular edema (RE- SOLVE study): a 12-month, randomized, controlled, double- masked, multicenter phase ~ study[ ]]. Diabetes Care, 2010,33 ( 11 ) :2399-2405.
7Brown D M, Nguyen Q D, Marcus D M, et al. Long-term outcomes of ranibizumab therapy for diabetic macular ede- ma: the 36-month results from two phase lit trials: RISE and RIDE [ J ]. Ophthalmology, 2013,120 ( 10 ) : 2013- 2022.
